These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33132682)

  • 1. Evaluation of Glycemic Control and Cost Savings Associated With Liraglutide Dose Reduction at a Veterans Affairs Hospital.
    Imarhia FI; Malveaux JN
    Fed Pract; 2020 Oct; 37(10):447-451. PubMed ID: 33132682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia.
    Alanazi NK; Ghoraba MA
    J Family Med Prim Care; 2020 Aug; 9(8):3933-3936. PubMed ID: 33110789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
    Inoue K; Maeda N; Fujishima Y; Fukuda S; Nagao H; Yamaoka M; Hirata A; Nishizawa H; Funahashi T; Shimomura I
    Diabetol Metab Syndr; 2014; 6(1):95. PubMed ID: 25237400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
    Kielgast U; Krarup T; Holst JJ; Madsbad S
    Diabetes Care; 2011 Jul; 34(7):1463-8. PubMed ID: 21593296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.
    Mosikian AA; Golikova TI; Martjanova MV; Babenko AY
    Future Sci OA; 2022 Mar; 8(3):FSO779. PubMed ID: 35251693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
    Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
    Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
    Alsafwani DM; Alotaibi HN; Alzaid JA; Alghamdi A; Almakhaita HM
    Cureus; 2022 Mar; 14(3):e23554. PubMed ID: 35371841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.
    Deerochanawong C; Kosachunhanun N; Gadekar AV; Chotikanokrat P; Permsuwan U
    Clinicoecon Outcomes Res; 2019; 11():423-430. PubMed ID: 31372015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 19. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.